CareCloud, Inc. (NASDAQ: CCLD) heads into the week of 23 November 2025 with fresh earnings, new guidance, and a high‑profile dividend plan reshaping the narrative around this small‑cap healthcare IT and AI stock.
As markets are closed today (Sunday), the latest reference price for CareCloud is $2.94 per share, Friday’s close on 21 November 2025, up about 3.2% on the day. [1] That puts the company’s market value at roughly $125 million, with a 52‑week trading range between about $1.14 and $4.84 per share. [2]
Below is a detailed, news‑driven look at CareCloud stock as of 23 November 2025, based on all the latest public information.
1. CareCloud stock today: price, valuation and trading snapshot
- Last close (21 Nov 2025): $2.94, up 3.16% on the day. [3]
- Day’s range (21 Nov): roughly $2.83 – $2.98. [4]
- 52‑week range: about $1.14 – $4.84. [5]
- Market cap: ~$124.6 million. [6]
- Shares outstanding: ~42.4 million. [7]
- TTM revenue: around $114.3 million. [8]
- TTM net income & EPS: about $2.38 million in net income and $0.08 EPS, implying a trailing P/E near 39 at the latest price. [9]
- Forward P/E: roughly 27, based on current consensus. [10]
- Average daily volume: around 250,000 shares. [11]
Over the past year, CareCloud’s share price is up only a few percent overall, despite sharp swings along the way, underscoring the stock’s high volatility typical of small‑cap, turnaround‑stage tech names. [12]
2. What’s new as of 23 November 2025?
There is no brand‑new press release dated exactly 23 November, but CareCloud has issued multiple material announcements in November 2025 that are still driving the story today:
- Q3 2025 earnings and a second raise to full‑year guidance (6 November 2025)
- A double dividend” catch‑up plan for its Series B preferred stock (10 November 2025)
- Ongoing impact from the Medsphere acquisition and related guidance hike (Sept–Aug 2025)
- Rapid build‑out of a 500‑person healthcare AI Center of Excellence (since April 2025)
Let’s unpack each of these and why they matter for CCLD today.
3. Q3 2025 earnings: six straight profitable quarters and guidance raised again
On 6 November 2025, CareCloud reported its third‑quarter 2025 results and delivered another profitable period while raising its full‑year outlook. [13]
Q3 2025 by the numbers
For the quarter ended 30 September 2025:
- Revenue: $31.1 million, up 9% year‑over‑year from $28.5 million. [14]
- GAAP net income: $3.1 million (unchanged from the prior‑year quarter), marking the sixth consecutive quarter of positive GAAP net income. [15]
- GAAP EPS: $0.04 versus a $0.04 loss in Q3 2024, an $0.08 per‑share swing. [16]
- Adjusted net income: $4.4 million, up about 27% from $3.5 million. [17]
- Adjusted EBITDA: $7.7 million, up 13% year‑over‑year. [18]
For the first nine months of 2025:
- Revenue: $86.1 million, up about 4% vs. the same period in 2024.
- GAAP net income: $7.9 million, up 74% year‑over‑year.
- Adjusted EBITDA: $19.9 million, up 17%. [19]
A Q3 recap from PRISM MarketView and other outlets emphasized that CareCloud is pairing modest top‑line growth with stronger profitability, highlighting higher margins, consistent cash generation, and the contribution from recent acquisitions. [20]
Full‑year 2025 guidance raised
With Q3, management raised guidance for the second time this year:
- 2025 revenue: now $117–$119 million (up from an initial $111–$114 million, and above the post‑Medsphere range of $116–$118 million). [21]
- Adjusted EBITDA: expected at $26–$28 million for 2025. [22]
- GAAP EPS: projected at $0.10–$0.13 for the full year. [23]
Earlier, right after closing the Medsphere Systems Corporation acquisition, CareCloud had lifted its 2025 revenue guidance to $116–$118 million and introduced a 2026 revenue outlook of $128–$130 million, signalling double‑digit growth expectations into next year. [24]
In short, the November guidance hike confirms that the acquisition and AI strategy are tracking at least as well as initially hoped.
4. Double dividends” on Series B preferred stock: what changed on 10 November?
On 10 November 2025, CareCloud announced a formal plan to pay double monthly dividends” on its 8.75% Series B Preferred Stock (CCLDO) beginning in January 2026. [25]
Key points of the plan:
- The company has 14 months of accumulated and unpaid dividends on the Series B preferred, covering November 2023 through December 2024, totalling about $3.9 million or $2.55 per share. [26]
- Starting with the January 2026 dividend (record date 31 January 2026; expected payment mid‑February), CareCloud plans to pay:
- one regular monthly dividend, plus
- one extra catch‑up” payment each month,
until the arrears are fully cleared. [27]
- Management expects the arrears to be fully paid off by the end of Q1 2027. [28]
- The company states that all of this will be funded from internally generated cash flow, with no issuance of new common shares, avoiding dilution for CCLD holders. [29]
Earlier in 2025, CareCloud had reinstated regular monthly dividends on both its Series A and Series B preferred shares and began making additional payments to chip away at arrears. [30] The November announcement essentially formalizes a clear, time‑bound catch‑up schedule for the remaining Series B backlog.
Why this matters for common shareholders
Although this specific plan targets the preferred stock, it has implications for the common:
- It signals management’s confidence in recurring revenues and free cash flow, because the company is committing to multi‑year catch‑up payments without external capital. [31]
- It continues the cleanup of a complex capital structure that had previously seen suspended preferred dividends, a mandatory conversion of Series A preferred shares, and a delisting of the Series A preferred from Nasdaq in March 2025. [32]
- By keeping the plan cash‑only, management avoids further dilution of common shareholders, which is a key concern for microcap investors.
For now, CareCloud’s common stock still does not pay a regular dividend, as reflected in current data providers. [33] The income story is primarily about the preferred securities, while common holders are leveraged to growth and multiple expansion.
5. Medsphere, MAP App & Marketware: transforming into a broader hospital IT player
A big part of the 2025 thesis for CareCloud stock revolves around its aggressive M&A strategy in hospital IT and analytics.
Medsphere acquisition (closed August 2025)
On 25 August 2025, CareCloud announced that it had closed its acquisition of the business assets of Medsphere Systems Corporation, a long‑standing provider of enterprise inpatient and ambulatory solutions. [34]
Highlights:
- Medsphere brings 600+ hospital and health system clients across all 50 U.S. states and territories, and a 23‑year operating history. [35]
- Its product suite includes:
- CareVue inpatient EHR,
- RCM Cloud revenue cycle platform,
- Wellsoft emergency department information system,
- HealthLine supply chain tools,
- ChartLogic ambulatory EHR and practice management,
- and managed IT services such as implementation and help desk. [36]
- Management has called the deal one of the most transformational transactions” in the company’s history, positioning CareCloud as an affordable, AI‑enabled alternative for small and mid‑size hospitals that find large EHR vendors too expensive. [37]
The total purchase price was about $16.5 million, part‑funded via a new $10 million credit facility with Provident Bank (with roughly $8.3 million drawn) and the rest from internal cash flow. [38] The credit line carries an interest rate of SOFR + 3%, a two‑year term, and replaced a prior Wells Fargo acquisition note on more favorable terms. [39]
By Q3, CareCloud had already reduced borrowings on this facility from $8.3 million to $4.9 million, while continuing to pay preferred dividends out of free cash flow—another sign of improved balance‑sheet flexibility. [40]
HFMA’s MAP App and Marketware (September 2025)
CareCloud has layered additional hospital‑focused assets on top of Medsphere:
- HFMA’s MAP App (agreement announced 29 September 2025) – a respected benchmarking tool for hospital revenue cycle performance, acquired with a long‑term joint marketing agreement with the Healthcare Financial Management Association. [41]
- Marketware (unveiled 25 September 2025) – a physician relationship management and analytics platform, now positioned as a strategic growth solution for hospitals to manage referrals, align physicians, and drive service line growth. [42]
Analyst summaries highlight that these deals effectively turn CareCloud into a vertically integrated hospital IT and analytics platform, expanding its addressable market well beyond outpatient practices. [43]
6. AI Center of Excellence: scaling to 500 AI professionals by late 2025
One of the most distinctive parts of the CareCloud story—and a frequent focus in recent coverage—is its bet on healthcare‑specific generative AI.
On 28 April 2025, CareCloud officially launched its AI Center of Excellence (AI CoE), describing it as a major strategic initiative built on 25 years of clinical and financial data. [44]
Key details:
- The AI CoE started operations with over 50 AI engineers, data scientists and healthcare domain experts. [45]
- CareCloud plans to scale this team to around 500 AI professionals by Q4 2025, which, if achieved, would make it one of the largest dedicated healthcare AI centers in the world. [46]
- The initiative is fully self‑funded using operating cash flow and a low‑cost global delivery model, positioning CareCloud as a cost‑efficient competitor versus U.S.‑based AI rivals. [47]
- Focus areas include: AI‑driven clinical documentation, coding and claims automation; predictive analytics for reimbursement risk; AI‑powered patient engagement; and embedding AI into EHR and RCM platforms. [48]
In the Q3 release and earnings commentary, management repeatedly framed AI as central to its differentiation, noting that integrating AI into the newly acquired Medsphere and MAP App platforms is unlocking efficiency gains and cross‑sell opportunities. [49]
7. Earlier 2025 results: the turnaround story in context
To understand why investors are paying attention now, it’s worth looking at the full 2025 trajectory.
Q1 2025: first leg of the turnaround
In Q1 2025, CareCloud reported:
- Revenue of about $27.6 million, up ~6% year‑over‑year.
- GAAP net income of $1.9 million, compared with a small loss in Q1 2024.
- Adjusted EBITDA of $5.6 million, up more than 50% year‑over‑year. [50]
Management highlighted this as proof that AI‑driven efficiency and disciplined expense control were starting to show up in the numbers, with robust operating cash flow and a growing cash balance.
Q2 2025: positive EPS and strong cash flow
In Q2 2025, CareCloud continued the trend:
- Revenue: $27.4 million (slightly below the prior year’s $28.1 million, reflecting some portfolio optimization).
- GAAP net income: $2.9 million, up from $1.7 million in Q2 2024.
- GAAP EPS: $0.04 per share versus a $0.14 loss a year earlier.
- Adjusted EBITDA: about $6.5 million for the quarter.
- Operating cash flow (first six months): $12.5 million, up from $8.3 million in the prior‑year period. [51]
Those first two quarters laid the groundwork for the Q3 guidance raise and gave management the confidence to resume and then formalize preferred dividend payments.
8. Share price reaction: how CCLD traded around the November news
CareCloud’s stock has traded actively and with large swings around its recent announcements.
From price history data: [52]
- On 5 November 2025, the day before the Q3 release, CCLD closed around $2.95.
- On 6 November, after reporting Q3 and raising guidance, the stock surged to a close of about $3.47, a one‑day move of roughly +18% on heavy volume of nearly 2.4 million shares.
- The stock traded in the $3.30–$3.55 range in the days following, including around the 10 November dividend plan announcement.
- Through mid‑November, the price gradually drifted lower to the high‑$2s to low‑$3s range. By 21 November, CCLD closed at $2.94, still above pre‑earnings levels but well below its November intraday highs and its 52‑week peak of about $4.84. [53]
This pattern suggests that:
- Short‑term traders reacted strongly to the earnings and guidance surprise,
- while the broader market is still processing integration and execution risks, leading to consolidation after the spike.
9. Analyst targets and sentiment
CareCloud is lightly covered by Wall Street, but the data we do have is bullish:
- One major data provider lists an average 12‑month price target of about $5.75, with an upper estimate near $8.00 and a lower around $3.25. At Friday’s close, that implies roughly 90–100% upside if the target proves accurate. [54]
- The same source currently shows a Buy” recommendation based on that limited analyst coverage. [55]
- GuruFocus and other research outlets have highlighted that the Medsphere acquisition and AI investments raise CareCloud’s growth profile but also increase non‑cash amortization, which can pressure GAAP EPS even when cash generation is strong. [56]
Because only a small number of analysts follow CCLD, these targets should be treated with caution. For a thinly traded microcap, sentiment can shift quickly with any surprise—positive or negative.
10. Capital structure cleanup: Series A conversion and delisting
Behind the scenes, 2024–2025 has also been about simplifying CareCloud’s capital structure:
- On 11 March 2025, the company announced it would voluntarily delist its 11% Series A Preferred Stock (CCLDP) from the Nasdaq after a mandatory conversion of most Series A shares into common stock. [57]
- Under that conversion, each non‑material” Series A share (generally holders with fewer than 100,000 preferred shares) was converted into 7.3358 shares of common stock. [58]
- The delisting of CCLDP became effective around 31 March 2025. [59]
Combined with the resumption and catch‑up of preferred dividends and the move to double Series B payouts starting in 2026, these steps are slowly moving CareCloud away from a complex, stressed capital structure toward a more standard small‑cap equity plus one actively trading preferred series (CCLDO).
11. What to watch next for CareCloud stock
Looking forward from 23 November 2025, here are the key items on the radar for CCLD investors:
- Execution on 2025 guidance
- Delivering full‑year revenue near $117–$119 million and EPS of $0.10–$0.13 is critical to justifying current and future valuation multiples. [60]
- Integration of Medsphere, MAP App and Marketware
- The bull case assumes CareCloud can cross‑sell AI‑augmented hospital solutions across more than 600 Medsphere clients and new benchmarking and referral‑management tools, translating into accelerating growth in 2026 and beyond. [61]
- Scaling the AI Center of Excellence
- Investors will watch whether headcount truly approaches 500 AI professionals by late 2025 and whether those teams ship revenue‑generating products fast enough to beat well‑funded competitors. [62]
- Balance sheet and debt pay‑down
- The company aims to fully pay down Medsphere‑related borrowing by mid‑2026, supported by free cash flow. Progress here will influence how comfortable the market is with ongoing acquisition activity. [63]
- Preferred dividend catch‑up
- For both preferred and common shareholders, successful execution of the double‑dividend plan without resorting to equity issuance will be an important proof point for management’s capital discipline. [64]
- Next earnings date
- Third‑party data currently points to a late‑February / early‑March 2026 window for CareCloud’s next earnings release, but the exact date may change; investors should confirm via the company’s investor‑relations site closer to the event. [65]
12. Risks to keep in mind
Even with improving fundamentals, CCLD remains a high‑risk small‑cap stock. Key risk factors include:
- Integration risk: Medsphere, RevNu, MAP App, Marketware and other deals from 2024–2025 all require careful onboarding, tech integration and cultural alignment. Missteps could hurt margins or customer retention. [66]
- Competitive pressure: The healthcare IT and RCM markets are crowded with large incumbents and newer AI‑driven entrants. CareCloud must differentiate on price, features and AI capabilities. [67]
- Regulatory and reimbursement volatility: Changes in healthcare reimbursement rules, privacy regulations, or EHR certification standards could require costly product updates or pressure client budgets. [68]
- Balance sheet concentration: While leverage is modest, a misstep in acquisitions or a slowdown in cash flow could constrain growth or force less shareholder‑friendly capital raises. [69]
- Microcap liquidity: With a market cap near $125 million and relatively low daily dollar volume, the stock can be very volatile, and large orders can move the price quickly in either direction. [70]
13. Bottom line on CareCloud stock as of 23 November 2025
As of today, 23 November 2025, the CareCloud story looks very different from a year ago:
- The company has stitched together six straight profitable quarters, with improving margins and solid free cash flow. [71]
- It is transforming from a practice‑focused RCM and EHR vendor into a broader hospital IT and AI platform via Medsphere, MAP App and Marketware. [72]
- Management has raised 2025 revenue guidance twice and laid out an ambitious AI roadmap and dividend catch‑up plan that, if executed, could support further re‑rating of the stock. [73]
At the same time, CCLD remains a small, volatile name with meaningful execution and integration risk. Whether the recent rally can continue will depend on CareCloud’s ability to:
- hit or exceed its upgraded 2025 and 2026 targets,
- prove that its AI CoE and acquisitions deliver durable growth, and
- maintain balance‑sheet discipline while cleaning up past capital structure complexities.
For now, CareCloud sits at the intersection of healthcare IT, AI, and small‑cap turnaround investing—a combination that can reward patience if the thesis plays out, but one that also requires a high tolerance for volatility and fundamental risk.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment or trading advice. Always do your own research or consult a licensed financial advisor before making investment decisions.
References
1. finance.yahoo.com, 2. stockanalysis.com, 3. finance.yahoo.com, 4. stockanalysis.com, 5. stockanalysis.com, 6. stockanalysis.com, 7. stockanalysis.com, 8. stockanalysis.com, 9. stockanalysis.com, 10. stockanalysis.com, 11. www.investing.com, 12. www.investing.com, 13. www.nasdaq.com, 14. www.nasdaq.com, 15. www.nasdaq.com, 16. www.nasdaq.com, 17. www.nasdaq.com, 18. www.nasdaq.com, 19. www.nasdaq.com, 20. prismmarketview.com, 21. www.nasdaq.com, 22. www.nasdaq.com, 23. www.nasdaq.com, 24. www.globenewswire.com, 25. www.globenewswire.com, 26. www.globenewswire.com, 27. www.globenewswire.com, 28. www.globenewswire.com, 29. www.globenewswire.com, 30. www.globenewswire.com, 31. www.globenewswire.com, 32. www.nasdaq.com, 33. stockanalysis.com, 34. www.globenewswire.com, 35. www.globenewswire.com, 36. www.globenewswire.com, 37. www.globenewswire.com, 38. www.stocktitan.net, 39. www.stocktitan.net, 40. www.nasdaq.com, 41. carecloud.com, 42. carecloud.com, 43. www.ainvest.com, 44. www.globenewswire.com, 45. www.globenewswire.com, 46. www.globenewswire.com, 47. www.globenewswire.com, 48. www.globenewswire.com, 49. www.nasdaq.com, 50. stocktwits.com, 51. www.globenewswire.com, 52. stockanalysis.com, 53. stockanalysis.com, 54. www.investing.com, 55. www.investing.com, 56. www.gurufocus.com, 57. www.nasdaq.com, 58. www.nasdaq.com, 59. www.nasdaq.com, 60. www.nasdaq.com, 61. www.globenewswire.com, 62. www.globenewswire.com, 63. www.stocktitan.net, 64. www.globenewswire.com, 65. www.investing.com, 66. www.globenewswire.com, 67. en.wikipedia.org, 68. www.nasdaq.com, 69. www.globenewswire.com, 70. stockanalysis.com, 71. www.nasdaq.com, 72. www.globenewswire.com, 73. www.nasdaq.com
